Linscomb Wealth’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,804
| Closed | -$276K | – | 335 |
|
|
2026
Q1 | $276K | Buy |
+1,804
| New | +$277K | 0.01% | 299 |
|
|
2023
Q1 | – | Sell |
-3,437
| Closed | -$312K | – | 307 |
|
|
2022
Q4 | $312K | Buy |
+3,437
| New | +$289K | 0.02% | 277 |
|
|
2022
Q2 | – | Sell |
-3,437
| Closed | -$301K | – | 318 |
|
|
2022
Q1 | $301K | Buy |
3,437
+191
| +6% | +$16.5K | 0.01% | 291 |
|
|
2021
Q4 | $284K | Sell |
3,246
-2
| -0.1% | -$166 | 0.01% | 287 |
|
|
2021
Q3 | $266K | Buy |
3,248
+40
| +1% | +$3.6K | 0.01% | 287 |
|
|
2021
Q2 | $293K | Sell |
3,208
-177
| -5% | -$15.8K | 0.02% | 270 |
|
|
2021
Q1 | $289K | Sell |
3,385
-92
| -3% | -$8.26K | 0.02% | 270 |
|
|
2020
Q4 | $328K | Buy |
3,477
+46
| +1% | +$4.02K | 0.02% | 244 |
|
|
2020
Q3 | $298K | Sell |
3,431
-28
| -0.8% | -$2.43K | 0.02% | 240 |
|
|
2020
Q2 | $302K | Sell |
3,459
-148
| -4% | -$12.8K | 0.02% | 242 |
|
|
2020
Q1 | $297K | Buy |
3,607
+905
| +33% | +$80.7K | 0.03% | 329 |
|
|
2019
Q4 | $256K | Buy |
2,702
+13
| +0.5% | +$1.17K | 0.02% | 376 |
|
|
2019
Q3 | $234K | Buy |
2,689
+84
| +3% | +$7.54K | 0.02% | 246 |
|
|
2019
Q2 | $238K | Sell |
2,605
-143
| -5% | -$12.1K | 0.02% | 245 |
|
|
2019
Q1 | $237K | Hold |
2,748
| – | – | 0.02% | 235 |
|
|
2018
Q4 | $211K | Hold |
2,748
| – | – | 0.02% | 247 |
|
|
2018
Q3 | $212K | Sell |
2,748
-206
| -7% | -$15.2K | 0.02% | 266 |
|
|
2018
Q2 | $200K | Buy |
+2,954
| New | +$204K | 0.02% | 267 |
|
|
2018
Q1 | – | Sell |
-2,767
| Closed | -$208K | – | 274 |
|
|
2017
Q4 | $208K | Sell |
2,767
-81
| -3% | -$6.11K | 0.02% | 265 |
|
|
2017
Q3 | $219K | Sell |
2,848
-190
| -6% | -$14.3K | 0.02% | 247 |
|
|
2017
Q2 | $227K | Buy |
+3,038
| New | +$215K | 0.02% | 234 |
|
|
2016
Q4 | – | Sell |
-2,954
| Closed | -$209K | – | 265 |
|
|
2016
Q3 | $209K | Buy |
2,954
+174
| +6% | +$12.7K | 0.02% | 237 |
|
|
2016
Q2 | $206K | Buy |
+2,780
| New | +$192K | 0.02% | 235 |
|
|
2015
Q4 | – | Sell |
-2,513
| Closed | -$207K | – | 260 |
|
|
2015
Q3 | $207K | Buy |
2,513
+92
| +4% | +$8.19K | 0.02% | 245 |
|
|
2015
Q2 | $213K | Buy |
+2,421
| New | +$222K | 0.02% | 255 |
|
|
2013
Q4 | – | Sell |
-10,791
| Closed | -$742K | – | 244 |
|
|
2013
Q3 | $742K | Sell |
10,791
-669
| -6% | -$44.3K | 0.1% | 113 |
|
|
2013
Q2 | $726K | Buy |
+11,460
| New | +$746K | 0.1% | 112 |
|
Other funds holding NVS
Linscomb Wealth's NVS Position: Q2 2026 in Review
Linscomb Wealth sold out of Novartis (NVS) in Q2 2026, closing a stake of 1,804 shares — an estimated $276K sold.
Linscomb Wealth first reported a position in NVS in Q2 2013 and held it in 27 quarters. The position peaked at $742K in Q3 2013. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Linscomb Wealth reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
- Linscomb Wealth sold 1,804 Novartis shares in Q2 2026, an estimated $276K.
- Linscomb Wealth first reported a position in Novartis in Q2 2013 and held it in 27 quarters.
- Linscomb Wealth's Novartis position peaked at $742K in Q3 2013.
- 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Linscomb Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.